References/Publications for Skin Test of Bet v 1

Check all              

Select PubMed ID Description
7684629 Int Arch Allergy Immunol. 1993;101(1):89-94.

Studies on the allergenicity of the amino-terminal epitope (Bet v I 23-38) from
birch pollen allergen.

Vik H(1), Steinvåg SK, Elsayed S.


8568143 J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):95-103.

Induction of IgE antibodies with predefined specificity in rhesus monkeys with
recombinant birch pollen allergens, Bet v 1 and Bet v 2.

Ferreira FD(1), Mayer P, Sperr WR, Valent P, Seiberler S, Ebner C, Liehl E,
Scheiner O, Kraft D, Valenta R.


8789543 Clin Exp Allergy. 1996 Jan;26(1):50-60.

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet
v I, the major birch pollen allergen.

Menz G(1), Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, Suter
M, Boltz-Nitulescu G, Ebner C, Kraft D, Valenta R.


8627171 J Exp Med. 1996 Feb 1;183(2):599-609.

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the
major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for
immunotherapy.

Ferreira F(1), Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R,
Hoffmann-Sommergruber K, Scheiner O, Kraft D, Breitenbach M, Rheinberger HJ,
Ebner C.


8626988 J Allergy Clin Immunol. 1996 May;97(5):1100-9.

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2:
diagnostic value for birch pollen and associated allergies.

Pauli G(1), Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft
D, Valenta R.


9011868 Pneumologie. 1996 Sep;50(9):632-40.

[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v
1, the chief allergen of birch].

[Article in German]

Menz G(1), Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, Suter
M, Boltz-Nitulescu G, Ebner C, Kraft D, Valenta R.


9058691 J Allergy Clin Immunol. 1997 Mar;99(3):354-9.

Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity
reactions equal to those induced by natural Bet v 1 in the airways of patients
allergic to tree pollen.

Godnic-Cvar J(1), Susani M, Breiteneder H, Berger A, Havelec L, Waldhör T,
Hirschwehr R, Valenta R, Scheiner O, Rüdiger H, Kraft D, Ebner C.


9067529 Clin Exp Immunol. 1997 Mar;107(3):536-41.

Modulation of the allergic immune response in BALB/c mice by subcutaneous
injection of high doses of the dominant T cell epitope from the major birch
pollen allergen Bet v 1.

Bauer L(1), Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner
C.


9130500
Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):125-7.

Isoforms of atopic allergens with reduced allergenicity but conserved T cell
antigenicity: possible use for specific immunotherapy.

Ferreira F(1), Hirthenlehner K, Briza P, Breiteneder H, Scheiner O, Kraft D,
Breitenbach M, Ebner C.


9130536 Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):246-8.

Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic
fragments.

Vrtala S(1), Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR,
Valent P, Ebner C, Kraft D, Valenta R.


9130537 Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):249-51.

Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic
to birch pollen from six countries.

Elfman L(1), Svensson M, Lidholm J, Pauli G, Valenta R.


9472988 FASEB J. 1998 Feb;12(2):231-42.

Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential
use of hypoallergenic variants for immunotherapy.

Ferreira F(1), Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R,
Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger HJ, Scheiner O.


9802365 J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):579-91.

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the
IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a
quantitative IgE inhibition study with sera from different populations.

Niederberger V(1), Pauli G, Grönlund H, Fröschl R, Rumpold H, Kraft D, Valenta R,
Spitzauer S.


10571741 J Invest Dermatol. 1999 Nov;113(5):830-7.

Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and
tree pollen allergens by skin testing.

Heiss S(1), Mahler V, Steiner R, Spitzauer S, Schweiger C, Kraft D, Valenta R.


10931114 Clin Exp Allergy. 2000 Aug;30(8):1076-84.

Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with
rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a
French population.

Pauli G(1), Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D,
Valenta R.


10589007 J Allergy Clin Immunol. 1999 Dec;104(6):1239-43.

Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch
pollen.

Arquint O(1), Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ.


11003446 Allergy. 2000 Sep;55(9):827-35.

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II.
Side-effects.

Winther L(1), Malling HJ, Mosbech H.


11487876 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1999;(93):203-10.

Skin testing with wild-type recombinant birch pollen allergens and hypoallergenic
modified molecules.

Pauli G(1), Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, Kraft D,
Valenta R.


12209091 J Allergy Clin Immunol. 2002 Sep;110(3):435-42.

IgE to Bet v 1 and profilin: cross-reactivity patterns and clinical relevance.

Wensing M(1), Akkerdaas JH, van Leeuwen WA, Stapel SO, Bruijnzeel-Koomen CA,
Aalberse RC, Bast BJ, Knulst AC, van Ree R.


16272319 J Immunol. 2005 Nov 15;175(10):6645-50.

Dimerization of the major birch pollen allergen Bet v 1 is important for its in
vivo IgE-cross-linking potential in mice.

Schöll I(1), Kalkura N, Shedziankova Y, Bergmann A, Verdino P, Knittelfelder R,
Kopp T, Hantusch B, Betzel C, Dierks K, Scheiner O, Boltz-Nitulescu G, Keller W,
Jensen-Jarolim E.


17911617 J Immunol. 2007 Oct 15;179(8):5309-16.

Analysis of epitope-specific immune responses induced by vaccination with
structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

Pree I(1), Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, Cromwell O,
Gadermaier E, Egger C, Reider N, Horak F, Valenta R, Niederberger V.


18564326 Clin Exp Allergy. 2008 Sep;38(9):1514-25. doi: 10.1111/j.1365-2222.2008.03042.x.
Epub 2008 Jun 28.

Clinical effects of immunotherapy with genetically modified recombinant birch
pollen Bet v 1 derivatives.

Purohit A(1), Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, Weber
B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O.


19274924 J Investig Allergol Clin Immunol. 2009;19(1):13-20.

Component-resolved in vitro diagnosis in peach-allergic patients.

Gamboa PM(1), Sanz ML, Lombardero M, Barber D, Sánchez-Monje R, Goikoetxea MJ,
Antépara I, Ferrer M, Salcedo G.


25327982 Allergy. 2015 Jan;70(1):59-66. doi: 10.1111/all.12534. Epub 2014 Nov 30.

IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral
allergy syndrome.

Guhsl EE(1), Hofstetter G, Lengger N, Hemmer W, Ebner C, Fröschl R, Bublin M,
Lupinek C, Breiteneder H, Radauer C.


34126156 J Allergy Clin Immunol. 2021 Jun 11. pii: S0091-6749(21)00904-0. doi:
1016/j.jaci.2021.05.039. [Epub ahead of print]

Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch
allergy symptoms in a phase 1 study.

Gevaert P(1), De Craemer J(1), De Ruyck N(1), Rottey S(2), de Hoon J(3), Hellings
PW(4), Volckaert B(5), Lesneuck K(5), Orengo JM(6), Atanasio A(6), Kamal MA(6),
Abdallah H(6), Kamat V(6), Dingman R(6), DeVeaux M(6), Ramesh D(6), Perlee L(6),
Wang CQ(6), Weinreich DM(6), Herman G(6), Yancopoulos GD(6), O'Brien MP(7).